Supplemental Table 3. Absolute value and percent change for particle size in 20 subclasses.
|
A. Baseline | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sub class 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | |
| Measured value, nM | ||||||||||||||||||
| Placebo | 3.87 ± 2.94 | 12.71 ± 7.96 | 37.50 ± 14.24 | 45.27 ± 16.12 | 40.96 ± 13.08 | 190.43 ± 45.65 | 530.31 ± 121.46 | 302.87 ± 89.74 | 105.83 ± 31.47 | 24.47 ± 9.35 | 36.31 ± 8.46 | 33.70 ± 10.84 | 171.72 ± 76.06 | 1344.83 ± 722.57 | 4251.06 ± 907.49 | 5547.59 ± 777.31 | 2977.38 ± 457.00 | 1435.47 ± 268.65 |
| Evolocumab | 3.86 ± 3.48 | 13.00 ± 9.53 | 38.84 ± 16.54 | 47.99 ± 18.68 | 41.39 ± 13.64 | 196.07 ± 51.42 | 550.65 ± 148.49 | 311.85 ± 102.70 | 107.98 ± 34.19 | 25.42 ± 9.42 | 37.30 ± 8.57 | 33.74 ± 10.88 | 181.34 ± 100.18 | 1363.02 ± 832.96 | 4195.35 ± 898.01 | 5540.57 ± 803.46 | 2965.98 ± 429.02 | 1453.44 ± 274.55 |
|
B. Week 12 | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sub class 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | |||
| Measured value, nM | ||||||||||||||||||||
| Placebo | 3.79 ± 3.17 | 12.57 ± 8.97 | 37.38 ± 15.58 | 46.02 ± 16.86 | 40.85 ± 11.81 | 188.22 ± 46.13 | 528.18 ± 120.62 | 306.64 ± 96.71 | 107.17 ± 34.54 | 24.66 ± 9.70 | 36.37 ± 8.87 | 33.64 ± 9.93 | 172.76 ± 78.59 | 1358.35 ± 750.01 | 4191.19 ± 949.54 | 5457.31 ± 746.88 | 2947.62 ± 420.19 | 1445.52 ± 252.88 | ||
| Evolocumab | 2.62 ± 2.75 | 8.88 ± 6.96 | 21.18 ± 11.68 | 28.89 ± 12.94 | 23.45 ± 7.62 | 80.20 ± 30.74 | 192.96 ± 92.84 | 112.22 ± 57.02 | 39.85 ± 19.35 | 13.36 ± 5.65 | 20.20 ± 6.29 | 27.83 ± 11.25 | 187.14 ± 111.36 | 1641.56 ± 911.73 | 4579.64 ± 931.47 | 5511.89 ± 792.98 | 2928.78 ± 431.67 | 1394.76 ± 296.75 | ||
| Change from baseline, % | ||||||||||||||||||||
| Placebo | −9.66 (−34.68, 33.04) | −5.03 (−31.26, 32.53) | −0.38 (−16.78, 17.36) | 1.97 (−12.21, 15.25) | 1.70 (−11.96, 17.28) | −1.11 (−10.52, 8.66) | 0.26 (−8.45, 9.58) | 2.12 (−9.22, 12.72) | 1.68 (−10.36, 12.65) | 1.35 (−10.58, 12.41) | −0.38 (−7.01, 9.79) | 2.30 (−10.07, 13.75) | 1.87 (−10.58, 14.60) | 2.04 (−10.78, 18.13) | −1.09 (−8.75, 6.91) | −1.01 (−7.11, 4.35) | −1.26 (−8.87, 7.63) | 0.55 (−7.21, 10.25) | ||
| Evolocumab | −36.93 (−60.44, 0.88) | −31.96 (−52.18, −3.63) | −47.87 (−58.18, −34.39) | −39.44 (−53.57, −23.64) | −42.65 (−51.84, −32.00) | −60.10 (−66.54, −52.20) | −65.99 (−72.91, −57.38) | −65.69 (−72.44, −55.41) | −64.23 (−71.45, −54.62) | −47.45 (−57.60, −35.92) | −46.51 (−54.89, −38.21) | −19.15 (−33.98, −3.34) | −0.86 (−12.64, 16.62) | 25.73 (5.00, 41.48) | 9.41 (0.19, 19.23) | −0.08 (−6.33, 6.39) | −0.95 (−9.67, 7.52) | −4.38 (−11.15, 4.61) | ||
|
C. Mean of weeks 10 and 12 | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sub class 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | |
| Measured value, nM | ||||||||||||||||||
| Placebo | 3.76 ± 2.69 | 12.40 ± 7.59 | 37.10 ± 13.62 | 45.74 ± 15.89 | 40.55 ± 11.37 | 185.63 ± 43.92 | 518.31 ± 114.33 | 301.27 ± 91.83 | 105.52 ± 32.62 | 24.61 ± 9.34 | 36.04 ± 8.42 | 33.39 ± 9.50 | 171.04 ± 76.47 | 1333.85 ± 715.05 | 4144.13 ± 892.49 | 5430.76 ± 715.39 | 2936.72 ± 393.33 | 1434.67 ± 234.14 |
| Evolocumab | 2.52 ± 2.29 | 8.44 ± 5.80 | 20.14 ± 10.10 | 27.91 ± 11.70 | 22.88 ± 7.36 | 75.87 ± 28.87 | 175.86 ± 83.77 | 101.19 ± 50.67 | 36.11 ± 16.93 | 12.62 ± 5.07 | 19.29 ± 5.79 | 27.32 ± 10.61 | 185.48 ± 109.08 | 1625.46 ± 884.02 | 4535.65 ± 883.84 | 5419.80 ± 719.77 | 2866.17 ± 403.34 | 1357.59 ± 268.80 |
| Change from baseline, % | ||||||||||||||||||
| Placebo | −2.82 (−32.21, 37.97) | −1.91 (−27.13, 31.85) | −2.73 (−16.32, 18.46) | 2.40 (−13.01, 15.80) | −0.06 (−11.97, 12.37) | −2.57 (−11.22, 6.46) | −1.42 (−9.73, 5.89) | 0.43 (−9.87, 9.72) | −0.68 (−10.61, 9.58) | 0.69 (−9.71, 12.44) | −0.13 (−7.56, 7.52) | 0.10 (−8.04, 10.89) | −0.18 (−9.59, 10.37) | 0.63 (−10.23, 13.77) | −2.08 (−9.14, 4.97) | −2.18 (−7.24, 3.78) | −2.26 (−7.39, 6.05) | 0.32 (−7.27, 7.02) |
| Evolocumab | −33.66 (−56.87, −2.70) | −32.80 (−52.85, −7.31) | −49.21 (−59.29, −37.82) | −42.26 (−52.41, −31.61) | −44.43 (−52.40, −35.06) | −62.40 (−68.02, −55.71) | −69.63 (−75.10, −62.59) | −69.07 (−74.54, −60.74) | −67.45 (−73.44, −59.98) | −50.34 (−59.81, −39.57) | −48.08 (−57.80, −40.56) | −20.51 (−32.75, −6.95) | 0.41 (−12.07, 14.50) | 23.22 (7.32, 43.57) | 8.01 (0.87, 15.82) | −1.74 (−7.15, 4.23) | −3.54 (−10.44, 5.50) | −7.95 (−12.80, 1.15) |
Data are expressed as mean ± SD or median (interquartile range).